Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

meningococcal infections/náusea

El enlace se guarda en el portapapeles.
9 resultados

Presenting features of meningococcal disease, public health messages and media publicity: are they consistent?

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE To investigate whether the presenting features of meningococcal disease as promoted in public health awareness material and in the print media accurately reflect the clinical features in patients admitted to Auckland hospitals with meningococcal disease January 1998 to June

[Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012].

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND During 2012 in Chile, there were 60 cases of serogroup W135 meningococcal disease, which accounts for 57.7% of identified serogroup cases. OBJECTIVE To describe main clinical features of patients with serogroup W135 meningococcal disease confirmed in 2012. METHODS Descriptive study of

[Gastrointestinal symptoms with meningococcal infection. Emergence of Neisseria meningitidis serogroup W.]

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND Meningococcal disease usually presents as meningitis and/or septicaemia, but can also present as pneumonia or arthritis. Since 2000, a worldwide increase in meningococcal disease is reported which is caused by a new virulent clone of serogroup W (MenW:cc11). This subtype is more likely to
Atypical clinical presentations associated with group W meningococcal disease (MenW) are well-described and include pneumonia, septic arthritis, endocarditis and epiglottitis/supraglottitis. Following anecdotal reports of teenagers presenting with predominantly gastrointestinal symptoms, we

Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015.

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His
Eculizumab has been developed as a breakthrough treatment for paroxysmal nocturnal hemoglobinuria (PNH). Not only for breakthroughs, eculizumab therapy is also known to increase the risk of invasive meningococcal infection. It has also been recently reported that, although rarely, administration of

Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Background: Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease.

Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients.

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens.

Eculizumab.

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed. CONCLUSIONS Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is
Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge